These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2314821)

  • 21. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
    Mattioli R; Lippe P; Massacesi C; Cappelletti C; Nacciarriti D; Bisonni R; Graziano F; Menichetti ET; Imperatori L; Testa E; Laici G; Balletra A; Silva RR
    Anticancer Res; 2004; 24(5B):3257-61. PubMed ID: 15510620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Milandri C; Gentile A; Salzano E; Amadori D
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):22-8. PubMed ID: 8941407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma.
    Lluch A; Azagra P; Cervantes A; Muñoz M; Alberola V; Santabarbara P; García-Conde J
    Oncology; 1994; 51(4):352-5. PubMed ID: 8208520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
    Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
    J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
    Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
    Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
    BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
    Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
    Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-intensive chemotherapy with etoposide-cyclophosphamide for advanced breast cancer. North American Marrow Transplant Group.
    Herzig RH; Lynch J; Christiansen NP; Fay JW; Davis MP; Herzig GP
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):28-32. PubMed ID: 8600546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
    Theodoulou M; Batist G; Campos S; Winer E; Welles L; Hudis C
    Clin Breast Cancer; 2009 May; 9(2):101-7. PubMed ID: 19433391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of vinorelbine + doxorubicin in advanced breast cancer.
    Lorvidhaya V; Kamnerdsupaphon P; Chitapanarux I; Srisukho S; Trakultivakorn H; Sumitsawan S; Sukthomya V; Tonusin A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1131-8. PubMed ID: 12938268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
    Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
    Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
    Hartman AR; Grekowicz A; Lum BL; Carlson RW; Schurman C; Sikic BI; Shapiro R; Stockdale FE
    Breast Cancer Res Treat; 2003 Nov; 82(1):61-9. PubMed ID: 14672404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer.
    Ardizzoni A; Canobbio L; Pronzato P; Repetto L; Serrano J; Benvenuto F; Simonassi C; Baracco F; Faravelli B; Nosenzo M
    Chemioterapia; 1986 Dec; 5(6):416-9. PubMed ID: 3026668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
    Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
    Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.